Semaglutide + Cagrilintide (10 mg): A Complete Scientific Explanation
The combination of Semaglutide + Cagrilintide represents an advanced dual-hormonal strategy for appetite regulation and weight management. Rather than intensifying a single pathway, this pairing targets two complementary and physiologically distinct satiety systems, resulting in deeper, more durable appetite control. This combination is often referred to conceptually as GLP-1 + amylin-based co-agonism.
Semaglutide + cagrilintide (10Mg)
Semaglutide —- GLP-1 Receptor Agonist
Semaglutide mimics the incretin hormone GLP-, acting primarily to:
- Suppress appetite via central nervous system signaling
- Slow gastric emptying
- Improve glucose-dependent insulin regulation
Its strength lies in reducing hunger and food reward, particularly cravings and large meal intake.
Cagrilintide — Long-Acting Amylin Analogue
Cagrilintide is a synthetic, long-acting analogue of amylin, a hormone co-secreted with insulin from pancreatic B-cells
Amylin’s physiological role includes:
- Promoting early satiety
- Slowing gastric emptying
- Regulating meal size and frequency
- Enhancing post-meal fullness
Cagrilintide is engineered to provide sustained amylin signaling without rapid degradation.
